Pittenger & Anderson Inc. Buys New Position in Edwards Lifesciences Co. (NYSE:EW)

Pittenger & Anderson Inc. purchased a new position in Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, Holdings Channel reports. The fund purchased 6,818 shares of the medical research company’s stock, valued at approximately $520,000.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Edwards Lifesciences by 0.6% during the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock valued at $3,577,163,000 after purchasing an additional 325,808 shares during the period. Wellington Management Group LLP grew its stake in shares of Edwards Lifesciences by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after acquiring an additional 1,390,427 shares during the period. Brown Advisory Inc. raised its stake in Edwards Lifesciences by 5.7% during the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after acquiring an additional 818,849 shares during the period. Northern Trust Corp lifted its holdings in Edwards Lifesciences by 3.9% during the third quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company’s stock valued at $440,446,000 after purchasing an additional 241,347 shares in the last quarter. Finally, WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its position in shares of Edwards Lifesciences by 16.8% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,100,000 shares of the medical research company’s stock worth $312,625,000 after purchasing an additional 590,000 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.7 %

NYSE EW traded down $0.60 on Thursday, hitting $88.01. 4,167,118 shares of the stock were exchanged, compared to its average volume of 3,828,266. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The firm has a market capitalization of $52.98 billion, a P/E ratio of 38.53, a P/E/G ratio of 4.35 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The stock has a fifty day moving average price of $90.23 and a two-hundred day moving average price of $78.69.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm’s revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 EPS. Research analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Mizuho boosted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Finally, Royal Bank of Canada raised their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $91.73.

Insider Transactions at Edwards Lifesciences

In related news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares in the company, valued at approximately $2,980,774.68. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the sale, the vice president now directly owns 34,814 shares in the company, valued at approximately $2,980,774.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the transaction, the vice president now owns 17,213 shares in the company, valued at approximately $1,566,038.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.